Details for Patent: RE48267
Which drugs does patent RE48267 protect, and when does it expire?
Patent RE48267 protects VOXZOGO and is included in one NDA.
This patent has forty-five patent family members in twenty-four countries.
Summary for Patent: RE48267
| Title: | Variants of C-type natriuretic peptide |
| Abstract: | The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis). |
| Inventor(s): | Daniel J. Wendt, Shinong Long, Sianna CASTILLO, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe |
| Assignee: | Biomarin Pharmaceutical Inc |
| Application Number: | US15/646,822 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent RE48267 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent RE48267
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | RE48267 | ⤷ Start Trial | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | ||||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-002 | Nov 19, 2021 | RX | Yes | Yes | RE48267 | ⤷ Start Trial | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | ||||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-003 | Nov 19, 2021 | RX | Yes | Yes | RE48267 | ⤷ Start Trial | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE48267
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2432489 | ⤷ Start Trial | LUC00248 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2432489 | ⤷ Start Trial | 301162 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2432489 | ⤷ Start Trial | CA 2022 00004 | Denmark | ⤷ Start Trial |
| European Patent Office | 2432489 | ⤷ Start Trial | 2022C/503 | Belgium | ⤷ Start Trial |
| European Patent Office | 2432489 | ⤷ Start Trial | 122022000008 | Germany | ⤷ Start Trial |
| European Patent Office | 2432489 | ⤷ Start Trial | C20220003 00351 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
